{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-087458","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2022-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.777821+00:00","generated_at":"2026-06-26T14:41:00.415749+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dr. Kauffman and Dr. Shacham to depart Karyopharm on May 31, 2022","bullets":["Dr. Michael Kauffman to depart as Senior Clinical Advisor; receives 18 months salary at $646,875/yr.","Dr. Sharon Shacham to depart as CSO; receives 18 months salary at $519,901/yr and consulting role.","Both executives get accelerated vesting of equity awards; options exercisable until March 1, 2025.","Dr. Shacham receives new grants: 90,000 stock options and 60,000 RSUs under consulting agreement.","Dr. Kauffman resigned from Board on March 22, 2022; waived nomination rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-087458","json":"https://secwatch.observer/filing/0001193125-22-087458.json","markdown":"https://secwatch.observer/filing/0001193125-22-087458.md","text":"https://secwatch.observer/filing/0001193125-22-087458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/0001193125-22-087458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/d344096d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T14:41:00.415749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fa4beb64b","claim":"Michael G. Kauffman resigned as Senior Clinical Advisor at Karyopharm Therapeutics Inc..","evidence_excerpt":"provides for Dr. Kauffman’s separation from employment as Senior Clinical Advisor on May 31, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/0001193125-22-087458-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Clinical Advisor"}],"fact_type":"executive_change"},{"claim_id":"78110912dc","claim":"Sharon Shacham resigned as Chief Scientific Officer at Karyopharm Therapeutics Inc..","evidence_excerpt":"provides for Dr. Shacham’s separation from employment as Chief Scientific Officer on the Separation Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/0001193125-22-087458-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}